APOE E4 is a determinant for Alzheimer type pathology in progressive supranuclear palsy

Neurology

Volumn 60, Issue 2, 2003, Pages 240-245

  Tsuboi, Yoshio ^a   Josephs, Keith A ^a   Cookson, Natalie ^a   Dickson, Dennis W ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

ADULT; AGED; ALLELISM; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN CORTEX; BRAIN REGION; BRAIN TISSUE; CORRELATION ANALYSIS; DEMOGRAPHY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; QUANTITATIVE ANALYSIS; RISK FACTOR; SENILE PLAQUE;

EID: 0037469193     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000044340.37138.A9     Document Type: Article

References (38)

1. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy: a heterogenous degeneration involving the brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia, and dementia. Arch Neurol 1964;10:333-339.
2. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
3. Hauw J-J, Daniel SE, Dickson DW, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44:2015-2019.
4. Ishizawa K, Ksiezak-Reding H, Davies P, et al. A double-labeling immunohistochemical study of tau exon 10 in Alzheimer's disease, progressive supranuclear palsy and Pick's disease. Acta Neuropathol 2000;100:235-244.
5. Mailliot C, Sergeant N, Bussiere T, Caillet-Boudin ML, Delacourte A, Buee L. Phosphorylation of specific sets of tau isoforms reflects different neurofibrillary degeneration processes. FEBS Lett 1998;21:201-204.
6. Delacourte A. Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration. Biomed Pharmacother 1994;48:287-295.
7. Evans DA, Funkenstein HH, Albert MS, et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA 1989;262:2551-2556.
8. Brousseau T, Legrain S, Berr C, Gourlet V, Vidal O, Amouyel P. Confirmation of the epsilon 4 allele of the APOE E gene as a risk factor for late-onset Alzheimer's disease. Neurology 1994;44:342-344.
9. Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. N Engl J Med 1998;338:506-511.
10. Tsuang D, Larson EB, Bowen J, et al. The utility of apolipoprotein E genotyping in the diagnosis of Alzheimer disease in a community-based case series. Arch Neurol 1999;56:1489-1495.
11. Berg L, McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and APOE E genotype. Arch Neurol 1998;55:326-335.
12. Mukaetova-Ladinska EB, Harrington CR, Roth M, Wischik CM. Presence of the apolipoprotein E type epsilon 4 allele is not associated with neurofibrillary pathology or biochemical changes to tau protein. Dement Geriatric Cogn Disord 1997;8:288-295.
13. Olichney JM, Hansen LA, Galasko D, et al. The apolipoprotein E epsilon 4 allele is associated with increased neuritic plaques and cerebral amyloid angiopathy in Alzheimer's disease and Lewy body variant. Neurology 1996;47:190-196.
14. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol 1996;39:62-70.
15. Zubenko GS, Stiffler S, Stabler S, et al. Association of the apolipoprotein E epsilon 4 allele with clinical subtypes of autopsy-confirmed Alzheimer's disease. Am J Med Genet 1994;54:199-205.
16. Hyman BT, Gomez-Isla T, Rebeek GW, et al. Epidemiological, clinical, and neuropathological study of apolipoprotein E genotype in Alzheimer's disease. Ann NY Acad Sci 1996;802:1-5.
17. Chen L, Baum L, Ng HK, Chan LY, Pang CP. Apolipoprotein E genotype and its pathological correlation in Chinese Alzheimer's disease with late onset. Hum Pathol 1999;30:1172-1177.
18. Ohm TG, Scharnagi H, Marz W, Bohl J. Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's diseaserelated lesions. Acta Neuropathol 1999;98:273-280.
19. Ghebremedhin E, Schultz C, Braak E, Braak H. High frequency of apolipoprotein E epsilon4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes. Exp Neurol 1998;153:152-155.
20. Warzok RW, Kessler C, Apel G, et al. Apolipoprotein E4 promotes incipient Alzheimer pathology in the elderly. Alzheimer Dis Assoc Disord 1998;12:33-39.
21. Mann DM, McDonagh AM, Pickering-Brown SM, Kowa H, Iwatsubo T. Amyloid beta protein deposition in patients with frontotemporal lobar degeneration: relationship to age and apolipoprotein E genotype. Neurosci Lett 2001;25:161-164.
22. Tabaton M, Rolleri M, Masturzo P, et al. Apolipoprotein E epsilon 4 allele frequency is not increased in progressive supranuclear palsy. Neurology 1995;45:1764-1765.
23. Anouti A, Schmidt K, Lyons KE, et al. Normal distribution of apolipoprotein E alleles in progressive supranuclear palsy. Neurology 1996;46:1156-1157.
24. Schneider JA, Gearing M, Robbins RS, de l'Aune W, Mirra SS. Apolipoprotein E genotype in diverse neurodegenerative disorders. Ann Neurol 1995;38:131-135.
25. Litvan I, Saunders AM. Apolipoprotein E4 (epsilon) allele does not affect the onset or symptom severity in progressive supranuclear palsy. Arch Neurol 1998;55:752-754.
26. Morris HR, Vaughan JR, Datta SR, et al. Multiple system atrophy/progressive supranuclear palsy: alpha-synuclein, synphilin, tau, and APOE. Neurology 2000;26:1918-1920.
27. Morris HR, Schrag A, Nath U, et al. Effect of ApoE and tau on age of onset of progressive supranuclear palsy and multiple system atrophy. Neurosci Lett 2001;312:118-120.
28. Crystal HA, Dickson DW, Sliwinski M, et al. Pathological markers associated with normal aging and dementia in the elderly. Ann Neurol 1993;34:566-573.
29. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
30. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1105.
31. Hyman BT, Trojanowski JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol 1997;56:1095-1097.
32. Dickson DW. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging 1997;18(4 suppl):S21-6.
33. Crook R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods 1994;53:125-127.
34. Verny M, Duyckaerts C, Agid Y, Hauw JJ. The significance of cortical pathology in progressive supranuclear palsy: clinico-pathological data in 10 cases. Brain 1999;119:1123-1136.
35. Davignon J, Gregg RE, Sing CF. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988;8:1-21.
36. Harrington CR, Louwagie J, Rossau R, et al. Influence of apolipoprotein E genotype on senile dementia of the Alzheimer and Lewy body types: significance for etiological theories of Alzheimer's disease. Am J Pathol 1994;145:1472-1484.
37. Dickson DW, Crystal HA, Mattiace LA, et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol Aging 1992;13:179-189.
38. Rogers J, Morrison JH. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer's disease. J Neurosci 1985;5:2801-2808.